GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2009

XTL Obtains Rights to Use Bio-GAL's Recombinant Erythropoietin as a Myeloma Treatment

XTL Obtains Rights to Use Bio-GAL's Recombinant Erythropoietin as a Myeloma Treatment

XTL enters asset purchase agreement with Bio-GAL

  • XTL Biopharmaceuticals entered into an asset purchase agreement with Bio-GAL for the rights to a use patent on the recombinant erythropoietin, rHuEPO, to develop a treatment for multiple myeloma. XTL will issue ordinary shares just under 50% of the current issued and outstanding share capital of the company.

    Bio-GAL will receive a milestone payment of $10 million upon the successful completion of a Phase II trial and 1% in royalties on net sales of the product. XTL's board of directors reserves the right to issue additional ordinary shares to Bio-GAL in lieu of the milestone payment.

    The transaction is expected to close in the second or third quarter. Erythropoietin is used as a therapeutic agent in kidney disease and cancer-related anemia. It is produced by recombinant DNA technology in mammalian cell culture.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?